- Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
- Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
- Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
- Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
More ▼
Key statistics
On Friday, Kiromic Biopharma Inc (KRBP:QBB) closed at 2.22, -45.59% below its 52-week high of 4.08, set on Jul 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.22 |
Low | 2.22 |
Bid | -- |
Offer | -- |
Previous close | 2.22 |
Average volume | 2.71k |
---|---|
Shares outstanding | 1.29m |
Free float | 886.98k |
P/E (TTM) | -- |
Market cap | 2.86m USD |
EPS (TTM) | -29.21 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 18:19 BST.
More ▼